36798-09-1 Usage
Explanation
The molecular formula represents the number of atoms of each element present in a molecule of the compound.
Explanation
The color and physical state of the compound, which can be useful for identification and handling purposes.
Explanation
The molecular weight is the mass of one mole of the compound, which can be used to calculate the mass of a given number of moles.
Explanation
The chemical structure describes the arrangement of atoms and functional groups in the molecule, which determines its chemical properties and reactivity.
Explanation
The fields in which the compound is commonly used, indicating its versatility and potential for various applications.
Explanation
The compound can be hazardous if not properly managed, emphasizing the need for safety precautions during its use and storage.
Explanation
The compound's frequent use in laboratory settings for specific applications, highlighting its importance in scientific research and development.
Appearance
Yellowish powder
Molecular weight
336.14 g/mol
Chemical structure
Benzene ring substituted with a benzyl group, a bromine atom, a methoxy group, and a nitro group
Applications
Organic synthesis, research, pharmaceuticals, dyes, and pesticides
Hazardous nature
Requires caution in handling and storage
Lab use
Commonly used in labs for organic synthesis and research purposes
Check Digit Verification of cas no
The CAS Registry Mumber 36798-09-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,6,7,9 and 8 respectively; the second part has 2 digits, 0 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 36798-09:
(7*3)+(6*6)+(5*7)+(4*9)+(3*8)+(2*0)+(1*9)=161
161 % 10 = 1
So 36798-09-1 is a valid CAS Registry Number.
36798-09-1Relevant academic research and scientific papers
AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS
-
Page/Page column 76, (2019/01/06)
The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.
NOVEL COMPOUND FOR IMAGING TAU PROTEIN ACCUMULATED IN THE BRAIN
-
Paragraph 0177, (2014/09/02)
The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrog
